Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging.
This Molecular Tumor Board presents a case of a patient with advanced stage high grade serous ovarian cancer whose OmniSeq INSIGHT testing revealed a BRCA1 mutation. Join us as we discuss next diagnostic steps, homologous recombination deficiency and treatment implications.